22 July 2026

Lupin licenses oncology assets to Kaveri Therapeutics

This corporate licensing deal serves as a minor illustrative example of private sector R&D investment in the pharmaceutical industry, which is relevant to the broader context of health sector development and industrial growth.

Questions

1. Discuss the significance of strategic licensing and spin-off models in the Indian pharmaceutical industry's efforts to enhance global R&D capabilities in oncology. 150 words
   Attempt this — 150 words in 8 min

   0 / 150 words 8:00 Reset

Prelims

1. Which of the following best describes the recent licensing arrangement between Lupin and Kaveri Therapeutics?

   1. A Kaveri Therapeutics licensed its proprietary oncology technology to Lupin for $1.6 million.
   2. B Lupin licensed two oncology programmes to Kaveri in exchange for an 82.2% equity stake.
   3. C Lupin acquired Kaveri Therapeutics as a wholly-owned subsidiary.
   4. D Lupin sold its entire oncology division to Kaveri Therapeutics for $1.6 million.